Acumen Pharmaceuticals, Inc. (ABOS)
$
2.4
+0.15 (6.25%)
Key metrics
Financial statements
Free cash flow per share
-2.0429
Market cap
145.4 Million
Price to sales ratio
0
Debt to equity
0.3310
Current ratio
6.0190
Income quality
0.9273
Average inventory
0
ROE
-0.9741
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing therapies for Alzheimer's disease, has a weighted average number of shares outstanding at 60,013,277.00 highlighting the company's shareholder base. The company reported a net loss of -$102,329,000.00 indicating challenges in its operations as it navigates the complexities of drug development. The gross profit ratio stands at 0.00 reflecting the efficiency of the company's production and sales operations, despite the inherent risks in the biopharmaceutical landscape. Additionally, Acumen incurred an interest expense of $4,068,000.00 which underscores its debt servicing obligations while pursuing innovation in therapeutic solutions. The company achieved a revenue of $0.00 indicating its niche market focus and commitment to addressing unmet needs in the treatment of Alzheimer's disease through its targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody currently in Phase I clinical trials targeting soluble amyloid-beta oligomers. In the financial market, the stock is affordable at $1.26 making it suitable for budget-conscious investors seeking entry points into emerging biopharmaceutical opportunities. However, the stock has a low average trading volume of 562,754.00 indicating lower market activity that may influence liquidity for potential investors. With a market capitalization of $145,376,220.00 the company is classified as a small-cap player, which often involves higher volatility but also the potential for substantial growth. Acumen Pharmaceuticals is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and advancing the development of new therapies. Furthermore, it belongs to the Healthcare sector, driving innovation and growth as it undertakes its mission to enhance the lives of individuals affected by Alzheimer's disease through its promising research and development initiatives.
Is Acumen Pharmaceuticals, Inc. (ABOS) a good investment?
Investing in Acumen Pharmaceuticals, Inc. (ABOS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Acumen Pharmaceuticals, Inc. (ABOS)'s stock forecast?
Analysts predict Acumen Pharmaceuticals, Inc. stock to fluctuate between $0.86 (low) and $3.05 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Acumen Pharmaceuticals, Inc.'s market capitalization?
As of 2026-02-06, Acumen Pharmaceuticals, Inc.'s market cap is $145,376,220, based on 60,573,425 outstanding shares.
How does Acumen Pharmaceuticals, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Acumen Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Acumen Pharmaceuticals, Inc. (ABOS) stock?
To buy Acumen Pharmaceuticals, Inc. (ABOS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABOS. Place an order (Market, Limit, etc.).
What is the best time to invest in Acumen Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Acumen Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.71 | Growth: 58.33%.
Where can I find Acumen Pharmaceuticals, Inc.'s investor relations reports?
Visit https://acumenpharm.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Acumen Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Acumen Pharmaceuticals, Inc. stock?
All-time high: $19.46 (2021-08-30) | All-time low: $0.86 (2025-04-21).
What are the key trends affecting Acumen Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
defenseworld.net
a month ago
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 12,941 shares of the business's stock in a transaction on Friday, January 9th. The shares were sold at an average price of $1.76, for a total value of $22,776.16. Following the completion of the transaction, the chief executive officer owned 598,898 shares
defenseworld.net
a month ago
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS - Get Free Report) CFO Matt Zuga sold 6,888 shares of Acumen Pharmaceuticals stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $1.82, for a total transaction of $12,536.16. Following the completion of the sale, the chief financial officer owned 209,951
defenseworld.net
a month ago
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 8,143 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $1.82, for a total transaction of $14,820.26. Following the transaction, the chief executive officer owned 611,839 shares of the company's stock,
defenseworld.net
a month ago
Shares of Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS - Get Free Report) have earned an average rating of "Moderate Buy" from the five research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average
defenseworld.net
2 months ago
Acumen Pharmaceuticals (NASDAQ: ABOS - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation. Earnings and Valuation This table compares Acumen
defenseworld.net
2 months ago
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1 year
seekingalpha.com
3 months ago
Acumen Pharmaceuticals, Inc. ( ABOS ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Alex Braun - VP & Head of Investor Relations Daniel O'Connell - CEO & Director Matt Zuga - CFO & Chief Business Officer James Doherty - President & Chief Development Officer Eric Siemers - Chief Medical Officer Conference Call Participants Jason Zemansky - BofA Securities, Research Division Thomas Shrader - BTIG, LLC, Research Division Matthew Ryan Tan - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good day, and welcome to the Acumen Pharma Third Quarter 2025 Conference Call and Webcast. [Operator Instructions] As a reminder, this call may be recorded.
seekingalpha.com
5 months ago
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Citi's Biopharma Back to School Conference September 2, 2025 3:15 PM EDT Company Participants Daniel O'Connell - CEO & Director Matt Zuga - CFO & Chief Business Officer James Doherty - President & Chief Development Officer Presentation Unknown Analyst All right. Here we go.
globenewswire.com
5 months ago
NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in the following upcoming investor conferences.
seekingalpha.com
6 months ago
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants Alex Braun - VP & Head of Investor Relations Daniel J. O'Connell - CEO & Director Eric Siemers - Chief Medical Officer James Doherty - President & Chief Development Officer Matt Zuga - CFO & Chief Business Officer Conference Call Participants Jason Eron Zemansky - BofA Securities, Research Division Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Pete George Stavropoulos - Cantor Fitzgerald & Co., Research Division Trung Chuong Huynh - UBS Investment Bank, Research Division Operator Good day, and welcome to the Acumen Pharmaceuticals Second Quarter 2025 Conference Call and Webcast.
See all news
